title: Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study.
abstract: BACKGROUND
  The aim of this study was to investigate whether the efficacy of liraglutide observed in randomized controlled trials translates into therapeutic benefits in the French population during routine clinical practice.
  
  
  METHODS
  This observational, prospective, multicenter study included 3152 adults with type 2 diabetes who had recently started or were about to start liraglutide treatment. During 2 years of follow-up, an evaluation of the reasons for prescribing liraglutide, maintenance dose of liraglutide, changes in combined antidiabetic treatments, level of glycemic control, change in body weight and body mass index (BMI), patient satisfaction with diabetes treatment and safety of liraglutide were investigated. The primary study endpoint was the proportion of patients still receiving liraglutide and presenting with HbA1c <7.0% after 2 years of follow-up.
  
  
  RESULTS
  At the end of the study, 29.5% of patients maintained liraglutide treatment and reached the HbA(1c) target. Mean (±SD) HbA(1c), fasting plasma glucose concentration, body weight and BMI were significantly reduced from baseline [8.46% (±1.46) to 7.44% (±1.20); 180 (±60) to 146 (±44) mg/dL; 95.2 (±20.0) to 91.1 (±19.6) kg; 34.0 (±7.2) to 32.5 (±6.9) kg/m(2); respectively, all P < 0.0001]. Patient treatment satisfaction increased, with the mean diabetes treatment satisfaction questionnaire status version score increasing from 22.17 (±7.64) to 28.55 (±5.79), P < 0.0001. The main adverse event type was gastrointestinal, with a frequency of 10.9%, and the percentage of patients suffering ≥1 hypoglycemic episode decreased from 6.9% to 4.4%.
  
  
  CONCLUSIONS
  The results of the EVIDENCE study suggest that the effectiveness of liraglutide in real-world clinical practice is similar to that observed in randomized controlled trials.
  
  
  BACKGROUND
  Novo Nordisk A/S.
  
  
  BACKGROUND
  ClinicalTrials.gov identifier, NCT01226966.
authors.affiliation: Saint-Louis Hospital, Paris, France.
authors.forename: Jean-Francois
authors.initials: JF
authors.lastname: Gautier
authors.affiliation: Université Pierre and Marie Curie, Paris, France.
authors.forename: Luc
authors.initials: L
authors.lastname: Martinez
authors.affiliation: Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France.
authors.forename: Alfred
authors.initials: A
authors.lastname: Penfornis
authors.affiliation: INSERM, Villejuif, France.
authors.forename: Eveline
authors.initials: E
authors.lastname: Eschwège
authors.affiliation: Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Charpentier
authors.affiliation: Novo Nordisk, Paris, France.
authors.forename: Benoît
authors.initials: B
authors.lastname: Huret
authors.affiliation: Novo Nordisk, Paris, France.
authors.forename: Suliya
authors.initials: S
authors.lastname: Madani
authors.affiliation: Service de Diabétologie, CHU Rangueil, Toulouse, France. pierre.gourdy@inserm.fr.
authors.forename: Pierre
authors.initials: P
authors.lastname: Gourdy
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide / Q000627:therapeutic use*; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies
chemical_list: D001786:Blood Glucose; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069450:Liraglutide
keywords: BMI; Liraglutide; Observational; Type 2 diabetes; Weight